Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Tandem Diabetes Care (TNDM) Deferred Taxes (2019)

Tandem Diabetes Care filings provide 1 years of Deferred Taxes readings, the most recent being -$25000.0 for Q4 2019.

On a quarterly basis, Deferred Taxes changed N/A to -$25000.0 in Q4 2019 year-over-year; TTM through Sep 2021 was -$25000.0, a N/A change, with the full-year FY2020 number at -$2.1 million, down 8404.0% from a year prior.
Deferred Taxes hit -$25000.0 in Q4 2019 for Tandem Diabetes Care.
In the past five years, Deferred Taxes ranged from a high of -$25000.0 in Q4 2019 to a low of -$25000.0 in Q4 2019.